Genetic enzyme CYP2D6 variation was associated with outcomes in breast cancer

DiMarcantonio, Tina; Haigh, Christen; Harris, Jason; Lawrence, Leah
November 2009
Hem/Onc Today;11/10/2009, Vol. 10 Issue 21, p20
The article discusses a study by W. Schroth and colleagues about determining the association of genetic enzyme CYP2D6 with the clinical outcomes in breast cancer published in the "Journal of the American Medical Association."


Related Articles

  • Aromatase Inhibitors in Breast Cancer. Smith, Ian E.; Dowsett, Mitch // New England Journal of Medicine;6/12/2003, Vol. 348 Issue 24, p2431 

    Reviews the role of aromatase inhibitors, which provide approaches to endocrine treatment of breast cancer and assesses their potential for clinical use. Sources and mechanisms of action for aromatase inhibitors; Inhibition of aromatase in premenopausal women; Development of the first three...

  • Breast Cancer and Virus.  // Time;5/24/1971, Vol. 97 Issue 21, p50 

    The article reports on the medical discoveries related to breast cancer and its virus in the U.S. and India. As stated Parsis women are three times more likely to develop breast cancers than the rest of the Indians as the studies showed high concentrations of virus-like particles in their milk....

  • Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study. Lenner, P.; Wiklund, F.; Emdin, S.O.; Arnerlöv, C.; Eklund, C.; Hallmans, G.; Zentgraf, H.; Dillner, J. // British Journal of Cancer;2/15/99, Vol. 79 Issue 5/6, p927 

    To perform an epidemiological evaluation of the predictive value of p53 autoantibodies in breast cancer, we measured antibodies against p53 in serum samples from 165 breast cancer patients in comparison with serum samples from 330 healthy controls, selected from the same population as the cases...

  • News in brief.  // Nature Medicine;Jul2007, Vol. 13 Issue 7, p768 

    The article offers news briefs related to medical research. It is noted that the faculty at Standford University reject a ban on the use of research money from the tobacco industry. A research which confirms that aspirin prevents colon cancer by blocking the inflammation-inducing enzyme COX-2....

  • Treatment - Metastatic and Advanced Disease.  // Current Medical Literature: Breast Cancer;2006, Vol. 18 Issue 2, p54 

    Discusses two studies related to breast cancer treatment. "Antiangiogenic and Antitumor Effects of Bevacizumab in Patients With Inflammatory and Locally Advanced Breat Cancer"; "Fulvestrant in Women With Advanced Breast Cancer After Progression on Prior Aromatase Inhibitor Therapy: North...

  • Breast cancer facts. Komen, Susan G. // WWD: Women's Wear Daily;8/31/1994, Vol. 168 Issue 45, WWD p12 

    Presents several information on breast cancer from the Susan G. Komen Breast Cancer Foundation. Development of breast cancer among women before age 85; Projected number of breast cancer victims for 1994; Mortality rate for black women.

  • Telomerase activity in benign and malignant breast lesions: A pilot prospective study on... Villa, Raffaela; Folini, Marco; Zaffaroni, Nadia; Martelli, Gabriele; De Palo, Giuseppe; Daidone, Maria Grazia; Silvestrini, Rosella // JNCI: Journal of the National Cancer Institute;04/01/98, Vol. 90 Issue 7, p537 

    Focuses on the enzyme telomerase which medical researchers believe may contribute to tumorigenesis and neoplastic progression. Effort to determine at what stage of cancer development telomerase in reactivated; Why scientists have focused their efforts on defining the utility of assaying for...

  • Keep taking the aspirin. Wingfield, Karen // Cancer Nursing Practice;Nov2008, Vol. 7 Issue 9, p12 

    The article reports on a study by Canadian and Spanish researchers which has found a link between taking non-steroidal anti-inflammatory drugs (NSAIDS) and a reduced risk of breast cancer. The research found that NSAIDS play a role in inhibiting cycloxygenase, an enzyme involved in the synthesis...

  • Significance of survivin and Bcl-2 homologous antagonist/killer mRNA in detection of bone metastasis in patients with breast cancer. Zohny, Samir; El-Shinawi, Mohamed // Medical Oncology;Dec2011, Vol. 28, p108 

    The aim of this study was to assess the diagnostic value of survivin and Bcl-2 homologous antagonist/killer (Bak) mRNA in the detection of patients with bone metastatic breast cancer. This study included 92 patients with breast carcinoma (54 non-metastatic and 38 bone metastatic) and 31 patients...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics